Suzanne E. Hayman

发表

Prognostic impact of posttransplant FDG PET/CT scan in multiple myeloma.

D. Dingli, A. Dispenzieri, R. Kyle, 2021, Blood advances.

Impact of maintenance therapy post autologous stem cell transplantation for multiple myeloma in early and delayed transplant

D. Dingli, A. Dispenzieri, Shaji K. Kumar, 2022, Bone Marrow Transplantation.

The Effect of Duration of Lenalidomide Maintenance and Outcomes of Different Salvage Regimens in Patients with Multiple Myeloma (MM)

D. Dingli, A. Dispenzieri, R. Kyle, 2021, Blood Cancer Journal.

Impact of achieving a complete response to initial therapy of multiple myeloma and predictors of subsequent outcome

D. Dingli, A. Dispenzieri, R. Kyle, 2022, American journal of hematology.

Two types of amyloidosis presenting in a single patient: a case series

S. Ansell, A. Dispenzieri, S. Rajkumar, 2019, Blood Cancer Journal.

Low levels of interleukin-1 receptor antagonist (IL-1RA) predict engraftment syndrome after autologous stem cell transplantation in POEMS syndrome and other plasma cell neoplasms.

D. Dingli, A. Dispenzieri, Shaji K. Kumar, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Factors associated with favorable outcome after allogeneic hematopoietic stem cell transplantation for multiple myeloma

D. Dingli, A. Dispenzieri, Shaji K. Kumar, 2009, Leukemia & lymphoma.

Characteristics and risk factors for thrombosis in POEMS syndrome: A retrospective evaluation of 230 patients

D. Dingli, A. Dispenzieri, R. Kyle, 2021, American journal of hematology.

Thrombosis in multiple myeloma: Risk estimation by induction regimen and association with overall survival

D. Dingli, A. Dispenzieri, Shaji K. Kumar, 2022, American journal of hematology.

Value of bone marrow examination in determining response to therapy in patients with multiple myeloma in the context of mass spectrometry-based M-protein assessment

D. Dingli, A. Dispenzieri, Shaji K. Kumar, 2022, Leukemia.

A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myeloma

R. Fonseca, S. Vincent Rajkumar, D. Dingli, 2012, British journal of haematology.

Impact of the time interval between end of induction and autologous hematopoietic transplantation in newly diagnosed patients with multiple myeloma

D. Dingli, A. Dispenzieri, Shaji K. Kumar, 2022, Bone Marrow Transplantation.

Risk factors for severe infection and mortality In patients with COVID‐19 in patients with multiple myeloma and AL amyloidosis

R. Fonseca, D. Dingli, A. Chanan-Khan, 2022, American journal of hematology.

Lack of a caregiver is associated with shorter survival in myeloma patients undergoing autologous stem cell transplantation

D. Dingli, A. Dispenzieri, Shaji K. Kumar, 2022, Leukemia & lymphoma.

Value of bone marrow examination in determining response to therapy in patients with multiple myeloma in the context of mass spectrometry-based M-protein assessment

D. Dingli, A. Dispenzieri, Shaji K. Kumar, 2022, Leukemia.

An Open-Label Phase I Study of Metformin and Nelfinavir in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma.

F. Buadi, W. Gonsalves, Suzanne E. Hayman, 2024, Clinical lymphoma, myeloma & leukemia.

Association of Thrombocytopenia With Disease Burden, High-Risk Cytogenetics, and Survival in Newly Diagnosed Multiple Myeloma Patients Treated With Novel Therapies.

D. Dingli, A. Dispenzieri, M. Lacy, 2024, Clinical lymphoma, myeloma & leukemia.